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Despite tremendous eﬀorts on isolation of pluripotent equine embryonic stem (ES) cells, to date there are few reports about
successful isolation of ESCs and no report of in vivo diﬀerentiation of this important companion species. We report the induction
of pluripotency in adult equine ﬁbroblasts via retroviral transduction with three transcription factors using OCT4, SOX2,a n d
KLF4 in the absence of c-MYC. The cell lines were maintained beyond 27 passages (more than 11 months) and characterized.
The equine iPS (EiPS) cells stained positive for alkaline phosphatase by histochemical staining and expressed OCT4, NANOG,
SSEA1, and SSEA4. Gene expression analysis of the cells showed the expression of OCT4, SOX2 NANOG,a n dSTAT3.T h ec e l l
lines retained a euploid chromosome count of 64 after long-term culture cryopreservation. The EiPS demonstrated diﬀerentiation
capacity for the three embryonic germ layers both in vitro by embryoid bodies (EBs) formation and in vivo by teratoma formation.
In conclusion, we report the derivation of iPS cells from equine adult ﬁbroblasts and long-term maintenance using either of the
three reprogramming factors.
1.Introduction
Cartilage and tendon injuries are common features of tissue
damage in both humans and horses. These two tissues have a
poor vascular system with low mitotic ability and therefore a
limited ability for self-repair. The reduced performance and
reinjury create considerable attention for treatments [1].
Adult mesenchymal stem cells (MSCs), embryonic stem
cells (ESCs), and reprogrammed somatic cells such as in-
duced pluripotent stem (iPS) cells can provide potential
sourcesofcellsfortreatmentofcartilageandtendoninjuries.
MSCs can be isolated from diﬀerent sources such as bone
marrow aspirates [2], umbilical cord [3], and adipose tissue
[4] and have the ability to diﬀerentiate into diﬀerent cell
t y p e ss u c ha sm u s c l e ,c a r t i l a g e ,a n db o n e[ 5–7]. MSCs have
been used for treatment of cartilage injuries in equines and
humans. Although there were the early improvements in
cartilage injuries, no signiﬁcant or long-term recovery could
be observed [8, 9]. In addition, MSCs are limited in bone
marrow aspirates and need to be cultured after isolation
for at least 4 weeks and have limited in vitro diﬀerentiation
potential compared with ESCs [1, 10].
ES cells can overcome this limitation, as they can pro-
vide an inexhaustible supply of cell derivatives of all three
germlayers.DespitetremendouseﬀortsonisolationofESCs,
to date there are a few reports on isolation of equine ESCs,
which had limited success and no investigation of in vivo dif-
ferentiation of the isolated cells [11, 12]. Isolation of equine
ESCs is diﬃcult due to the shortage of oocytes and embryos,
as well as complexity associated with oocyte collection,
maturation,IVF,andinvitrocultureinthisspecies[13].Even
if ES cells can be successfully derived, a subsequent problem
is the anticipated immune rejection of the derivatives of2 Stem Cells International
ES cells by the recipient due to incompatibility of the ma-
jor histocompatibility complex (MHC) antigens because of
diﬀerences in genomic DNA compared with that of the
recipient [14].
There are alternative methods to produce autologous
cells lines via reprogramming of adult somatic cells to the
pluripotent states such as somatic cell nuclear transfer
(SCNT) [15, 16] and induced pluripotent stem (iPS) cells
[17]; however, limitation with derivation of equine ESCs
extend to SCNET-ESC isolation as well.
Takahashi and Yamanaka [17] reported the generation
of pluripotent cells from adult mouse ﬁbroblast following
retroviral-mediated transduction of four transcription fac-
tors, OCT4, SOX2, c-MYC,a n dKLF4. A number of stud-
ies have shown that iPS cells are similar to ESCs in mor-
phology and epigenetic status, expression of pluripotent
markers, and ability to diﬀerentiate into derivatives of all
three embryonic germ layers both in vivo and in vitro and
contribute to the germ-line in chimeric mice conﬁrming
their true pluripotency [17–19]. Therefore, these cells could
have therapeutic application in both human and animals.
Pluripotency has been induced in somatic cells from
human [20], primate [21], rat [22, 23] pigs [24–27], sheep
[21], and cattle [28].
More recently, the generation of equine iPS cell lines
fromfetalﬁbroblastsusingtransposon-baseddeliveryoffour
factors has been reported [29] .I nt h i ss t u d y ,w er e p o r t
the generations of equine-induced pluripotent stem (EiPS)
cells by retroviral-mediated transduction of adult equine
ﬁbroblasts using three transcription factors: OCT4, SOX2,
and KLF4, (OSK) without the protooncogene c-MYC, and
the pluripotent characteristics of the resulting EiPS cells have
been demonstrated both in vitro and in vivo.
2.MaterialsandMethods
Experimental procedures were carried out under the guide-
lines of the Monash University, Animal Ethics Committee,
and conducted according to the International guidelines for
Biomedical Research Involving Animals. All chemicals were
sourced from Sigma (Castle Hill, Australia) unless otherwise
stated.
2.1. Generation of Induced Pluripotent Stem (iPS) Cells from
Adult Equine Fibroblasts
2.1.1. Transfection, Isolation, and Culture of iPS Cells. Equine
iPS cells were generated as previously reported [28]. Brieﬂy,
for VSVG pseudotyped retroviral production 3 × 106 GP2
293 cells (Clontech; Scientiﬁx, Cheltenham, Australia) were
seeded in a 100mm culture dish one day before transfection
and incubated overnight at 37◦C, 5% CO2.p M X - b a s e d
retrovirus vectors encoding human DNA sequence of OCT4,
SOX2,a n dKLF4 were transfected into packaging cells (GP2
293) by FuGENE 6 transfection reagent (Roche, Castel Hill,
Australia), and the media were replaced by fresh media on
the following day. Viral supernatant was collected 48 and 72
hours later and ﬁltered through a 0.45μm cellulose acetate
ﬁlter.Viralsupernatantswerethenmixedwithpolybrenetoa
ﬁnalconcentrationof 8ng/mL. Adultequine ﬁbroblastswere
plated one day prior to transduction at a density of 1 × 105
cells per 100mm dish. The cells were incubated overnight
with the viral supernatant including equal contributions
of the factors and 8ng/mL polybrene. The following day,
transduction process was performed similar to the ﬁrst day.
ApMX-GFP andno-vectordisheswereprovidedasapositive
andnegativecontrol,respectively.Transducedcellswerethen
cultured in conventional medium containing α-minimum
essential medium (α-MEM) with deoxyribonucleosides and
ribonucleoside (Invitrogen, Mulgrave, Australia), supple-
mented with 2mmol/mL glutamax (Gibco, Invitrogen, Mul-
grave, Australia), 0.1% (v/v) Mercaptoethanol (Gibco), 1%
(v/v) nonessential amino acid (NEAA) (Gibco), 1% (v/v)
ITS (10μg/mL insulin, 5.5μg/mL 125 transferrin, 6.7ng/mL
selenium; Gibco), 5ng/mL human LIF (Millipore, North
Ryde, Australia), 10ng/mL βFGF (Millipore), 10ng/mL EGF
(Invitrogen), 0.5% (v/v) penicillin-streptomycin (Gibco),
and 20% (v/v) FBS. The medium was changed every other
day to maintain cell proliferation. After 12 to 16 days of
iPS induction, the best colonies based on equine ES cell-
likecolony’smorphologywerepickedandmanuallypassaged
onto mouse embryonic ﬁbroblasts (MEFs) inactivated with
4μg / m Lo fm i t o m y c i nCa n dp l a t e di na no r g a nc u l t u r ed i s h .
Colonies were manually cut into small clumps by insulin
syringe needles and expanded on the freshly inactivated
feeder layers to maintain the EiPS cell line. Seven cell lines
were initially produced and maintained in culture, and one
cell line was characterised in detail. The transduction eﬃ-
ciency of adult equine ﬁbroblast was evaluated by expression
of the pMX-GFP vector control, which was conducted in
parallel with the iPS induction experiments. Seventy-two
hours after pMX-GFP induction, cells were photographed
under a ﬂuorescence microscope, and the percentage of
cells expressing GFP was quantiﬁed by ﬂow cytometry.
Reprogramming eﬃciency evaluated by correlation of pMX-
GFP transduction eﬃciency with iPS cell colony numbers
was established [17].
2.1.2. FACS Analysis. Cells were incubated in incubator
(37◦C, 5% Co2) using 0.25% trypsin-EDTA (Invitrogen) for
ﬁve min and dissociated through pipetting. After spinning
at 400g for 3min, the pellet was resuspended and ﬁltered
through a 40μm cell strainer (BD Falcon) and analyzed by
a BD FACSCanto Flow Cytometer (BD).
2.2. Characterization of Equine iPS Cell Lines
2.2.1. Alkaline Phosphatase and Immunoﬂuorescence Staining.
Cells were ﬁxed for 15min in 4% (w/v) paraformalde-
hyde at room temperature and then stained. For alkaline
phosphatase (ALP) activity, the cells were stained by his-
tochemistry according to manufacturer’s instructions using
Alkaline Phosphatase Detection kit (Millipore). For OCT4
and NANOG staining, the cells were permeabilized in 0.2%
TritonX-100in3%(v/v)goatseruminDPBSfor15min.The
cells were incubated with 3%(v/v) goat serum in DPBS at RTStem Cells International 3
Table 1: List of primers used for RT-PCR.
Markers Primer F Primer R References
GAPDH GATTCCACCCATGGCAAGTTCCATGGCAC GCATCGAAGGTGGAAGAGTGGGTGTCACT
OCT4 TCTTTCCACCAGGCCCCCGGCTC TGCGGGCGGACATGGGGAGATCC
NANOG TCAAGGACAGGTTTCAGAAGCA GCTGGGATACTCCACTGGTG
SOX2 GGTTACCTCTTCCTCCCACTCCAG TTGCCTTAAACAAGACCACGAAA
STAT-3 TCTGGCTAGACAATATCATCGACCTT TTATTTCCAAACTGCATCAATGAATCT Li et al. [12]
β-Tubulin III CAGAGCAAGAACAGCAGCTACTT GTGAACTCCATCTCGTCCATGCCCTC Li et al. [12]
GATA-4 CTCTGGAGGCGAGATGGGACGGG GAGCGGTCATGTAGAGGCCGGCAGGCATT Li et al. [12]
α-Fetoprotein CTTACACAAAGAAAGCCCCTCAAC AAACTCCCAAAGCAGCACGAG Li et al. [12]
BMP4 TCGTTACCTCAAGGGAGTGG GGCTTTGGGGATACTGGAAT Pashaiasl et
al. [30]
OCT4 and SOX2 primers were based on primers speciﬁc for Homo sapiens primers. The sequences of these genes were blasted against horse nucleotide
sequences that have 95% and 94% coverage with the coding sequence of Equus caballus. BMP4 primers were designed on a bovine sequence that has 91%
coverage with the coding sequence of Equallus equa. STAT3, GATA4, β-tubulin III,a n dα-fetoprotein primers have been applied by Li et al. [12].
for 1hr to block nonspeciﬁc binding of the primary anti-
bodies and then incubated with primary antibodies raised
against mouse anti-human SSEA1 (Millipore, MAB4301),
mouse anti-human SSEA-4 (Millipore, MAB4304), mouse
anti-human OCT4 (Santa Cruz, sc-5279) and rabbit anti-
human Nanog (Abcam-ab21603) diluted at 1:100 in DPBS
containing 3% (v/v) goat serum overnight at 4◦C. The next
day the dishes were washed with DPBS three times and incu-
bated with secondary antibodies (diluted in DPBS 1:1000,
Alexa Flour 594 or 488, Invitrogen) for 1hr at RT. After
three washes with DPBS, the cells were counterstained with
1μg/mL Hoechst 33342 in DPBS for 10min at RT. Control
cell lines were treated mouse ESD3 and human ES cells as
well as negative control by omitting the primary antibodies
(Supplemental Figures 1 and 2) (In Supplementary Material
available on line at doi: 10.1155/2012/429160). Images were
captured on an Olympus Ix71 microscope.
2.2.2. RNA Extraction and RT-PCR Analysis of Gene Expres-
sion. Gene expression was analyzed by RT-PCR. Total RNA
was extracted from harvested cell samples using Dyn-
abeads mRNA DIRECT Micro Kit (Invitrogen) or using
the RNeasy kit (Qiagen, Doncaster, Australia) according
to the manufacturer’s instructions. RNA concentrations
were determined using the nanoDrop ND-1000 (NanoDrop
Technology, Australia). The extracted RNA was treated by
RQ1 DNase (Promega, South Sydney, Australia) to remove
any contaminating genomic DNA. cDNA was generated
using the superscript III enzyme as described before [30].
The ﬁrst strand cDNA was further ampliﬁed by PCR using
forward and reverse primers for speciﬁc genes. All samples
were checked for GAPDH to verify the success of the RT
reaction and then for other speciﬁc genes with individual
primers. PCR ampliﬁcation was performed in 50μLr e a c t i o n
containing 5μL DNA polymerase 10x reaction buﬀer, 3μL
MgCl2 (25mM), 1μLd N T Pm i x t u r e( 1 0m M ) ,0 . 4μLG o T a q
DNA Polymerase, 1μL( 1 0 μM) from each forward and
reverse primer, 1μLsampleandμLMilli-Qwater(Promega).
The PCR was processed in a MyCycler Thermal Cycler and
run for 35 cycles: denaturation (95◦C, 45s), annealing (55–
56◦C), and extension (72◦C, 45s) steps.
All PCR samples were analyzed by electrophoresis on a
2% (w/v) agarose gel. The sequence of primers used for PCR
and the product size are listed in the Table 1.
2.2.3.ChromosomeCountsofEquineiPSCellLines. Chromo-
some counts were performed at P15 and P22. To estimate
chromosome number, the cells were treated with 5-bromo-
2-deoxyuridine (BrdU) overnight and then with Colcemid
(Gibco) for a further 4 hours to suppress mitosis. After
treating with TrypLE Express (Invitrogen) and hydrating in
hypotonic KCL for 15min, they were washed and ﬁxed in
methanol and acetic acid in a ratio of 3:1 and centrifuged.
The ﬁxation and centrifuge process were repeated three
times. The ﬁxed cell pellet was resuspended in 50uL ﬁxative
and was dropped onto clean slides at RT. The slides were
stained with a freshly made staining solution containing
3mL of Leishman stain in 17mL Gurrapostrophes buﬀer
(Invitrogen) for 8min. The Leishman stain was prepared
by dissolving 2g Leishman powder in 1 liter methanol. A
coverslip was mounted on the slides with Histomount and
slides viewed using a light microscope under oil immersion
optics (Nikon C1) at 1000x magniﬁcation.
2.3. Diﬀerentiation Potential of Equine iPS Cell Line
2.3.1. Embryoid Body Formation. Equine iPS cells colonies
were mechanically dissociated into clumps with needles and
cultured on Petri dishes in medium containing α-MEM with
deoxyribonucleosides and ribonucleoside supplemented
withglutamax(Gibco),mercaptoethanol(Gibco),nonessen-
tial amino acid (NEAA, Gibco), ITS (insulin, transferrin,
selenium; Gibco), penicillin-streptomycin (Gibco), and FBS
[30]a t3 9 ◦C in a humidiﬁed gas environment of 5% CO2 in
air.Culturemediumwaschangedevery3days.Samplesfrom
attached and nonattached EBs were collected at two weeks
to check gene expression of ectodermal markers (β-tubulin4 Stem Cells International
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Figure1:FACsanalysisshowingGFPﬂuorescenceinadultequineﬁbroblastsfollowingpMX-GFPviraltransduction.(a)GFPﬂuorescencein
AEFsfollowingGP2293mediatedretroviraltransduction,scalebar200μM.(i)Brightﬁled.(ii)Greenﬁlter.FACsproﬁleofGFPﬂuorescence,
(b) Retroviral transduction using GP2 293 packaging cell. (c) Control EAFs.
III), endodermal markers (Gata4), and mesodermal markers
(BMP4) (Table 1)b yR T - P C Ra sd e s c r i b e db e f o r e .
2.3.2. Teratoma Formation. Equine iPS colonies were dis-
sociated into single cells and left on ice until preparation
of mice for injection. Five-week-old male SCID mice were
used for hind leg muscle injection of 2 × 106 EiPS cells.
All procedures were performed with sterile materials in a
biological safety cabinet. They were then monitored for
well-being and teratoma formation. A growth in the hind leg
was visible after approximately 8–10 weeks after injection.
Mice were humanely sacriﬁced; the tumor was dissected
out, washed in DPBS, ﬁxed in HistoChoic,e and embedded
in paraﬃn for histological analysis. The samples were
sectioned at 4μm thickness onto superfrost slides and
allowed to dry overnight. After staining with hematoxylin
and eosin, sections were observed using an Olympus Ix71
microscope.Stem Cells International 5
(a) (b)
(c) (d)
(e) (f)
Figure 2: Generation of EiPS cells. (a) Morphology of EiPS single colony growing from individual ﬁbroblast. (b) Typical colony of EiPS
cells on the MEF and colony selection. (c) Cutting individual colony for manual passaging. (d) Passaged pieces on the MEF. (e) Alkaline
phosphatase activity of EiPS cells scale bar 200μM. (f) Chromosome spread of EiPS cells.
3.Freezingand Thawing
One hour before freezing the cells, a cryofreezing container
containingisopropanolwasequilibratedat4◦C.Thecolonies
were dissociated into small clumps about 100 to 200 cells
and collected into 15mL falcon tube and washed by iPS
cellsmediumandcentrifugedfor3minat400g.Supernatant
was discarded, and clumps were resuspended in appropriate
amount of EiPS cells medium. Freezing medium which
consists of 80% FBS (JRH Bioscience, Australia) supple-
mented with 20% dimethyl sulphoxide (DMSO) was added
to prepared 500μL suspension including 80–100 clumps
of putative EiPS cells in iPS medium in a cryovial (Nunc,
Thermo Fisher, Scoresby, Australia). Then the vials were
initially frozen to −80◦C overnight and then transferred to a
LN2 tank at minus 196◦C for long-term storage. The thawing
process involved the placing of the cryovials containing the
clumps of EiPS cells in a water bath at 37◦C to be thawed,
and cells were transferred to a 15mL falcon tube, and then
10mL iPS cells medium was slowly added. The cells were
centrifuged for 3min at 400g, and then supernatant was
discarded, the pallet was resuspended with EiPS medium,
and clumps were implanted on fresh MEF in a culture dish
using insulin syringe needle.
4. Results
4.1. Generation of Induced Pluripotent Stem (iPS) Cells
from Adult Equine Fibroblasts. After two rounds of repeated
transduction with the three factors (OCT4, SOX2,a n dKlf4)6 Stem Cells International
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Figure 3: Gene expressions proﬁle of EiPS cells and genomic DNA analysis. (a) Genomic PCR conﬁrming the integration of the four
transgenes. (b) Gene expression of exogenous reprogramming factors. (c) Gene expression proﬁle of the EiPS cells compared to the parental
EAFs and MEF as feeder cells.
into adult equine ﬁbroblast, we achieved a transduction
eﬃciencyofgreaterthan60%ondaytwopostinfectionusing
pMX-GFPcontrolplasmid,whilenegativecontrolshowedno
GFP-marked cells (Figures 1(b) and 1(c)).
iPS cell colonies ﬁrst appeared on the day 8–10 postin-
fection with the dome-like and tightly packed structure.
They became large enough at around day 16 to be picked
and expanded. Colonies were isolated mechanically and
transferred onto prepared culture dishes containing MEF
layer and equine ES cell medium (Figure 2).
4.2. Characterization of Equine iPS Cell Line. EiPS cells had a
low cytoplasm to nuclear ratio and formed colonies to those
observed in cattle [28] .T h ec e l ll i n ew a sc h a r a c t e r i z e db y
molecularanalysis.Theintegrationofreprogrammingtrans-
genes into the genome of the cells was conﬁrmed by gDNA
PCRanalysisandexpressionofexogenousfactorexaminedat
passage 24 (Figures 3(a) and 3(b)). RT-PCR analysis showed
mRNA expression of key pluripotent markers including
OCT4, SOX2, NANOG,a n dSTAT3 (Figure 3(c)). Some
expression of Nanog was detected in equine ﬁbroblasts, and
STAT3 was also detected in the mouse embryonic feeder
cells using the primer pairs. The cell line expressed a high
level of alkaline phosphatase activity (Figure 2(e)). They
were positive for protein expression of OCT4, NANOG,
SSEA1, and SSEA4 as determined by immunoﬂuorescent
staining (Figure 4). Moreover, chromosome spreads revealed
a normal diploid chromosome count of 64 in metaphase
spreads at passage 15 (data not shown) and 22 (Figure 2(f)).
More than 90% of frozen EiPS cells clumps were recovered
after thawing and formed colonies after implanting on fresh
MEF feeder layer. Thawed cell lines survived and were
maintained for more than four passages without losing iPS
cell morphology.
4.2.1. Diﬀerentiation Potential of Equine iPS Cells. The EiPS
cells formed embryoid bodies after 5 days in suspension
culture, after which they were transferred to gelatin-coated
dishes to attach and develop outgrowths (Figures 5(a) and
5(b)). RT-PCR results demonstrated mRNA expression of
genes representative of the three embryonic germ layers
[11, 12], endoderm (α-fetoprotein), mesoderm (Gata4 and
BMP4), and ectoderm (β-tubulinIII)( Figure 5(c)). Equine
iPS cells formed teratomas 8 to 10 weeks after injection
containing cells of the three embryonic germ layers: endo-
derm (vessels), mesodermal cells (muscle), and ectoderm
(epidermal cells) (Figure 5(d)).
5. Discussion
Due to similarity in size, physiology, and immunology, large
animals are better models for human genetic or acquired
diseases compared with rodents. In addition, they have a
longer life span and have a heterogeneous genetic back-
ground which is similar to humans and unlike rodents;
therefore, they can provide a good model for long-term
experiments. Also about 95 equine genetic diseases share
a high homology with human genetic defects [13]. Fur-
thermore, equine can be an appropriate model for human
diseases such as osteoarthritis as well as a model for
musculoskeletal injuries as there are common features of the
athletic injuries in human and equine. Limited capability for
full functional repair of musculoskeletal injuries has limited
treatments outcomes [1]. Joint injuries and related illnesses
cost an estimated US$6.5 billion annually for the equine race
industry [13].
MSCs, ESCs, and iPS cells are options for research and
therapeutic applications regarding musculoskeletal injuries.
Compared with MSCs and ESCs, iPS cells are better as theyStem Cells International 7
(i)
(ii)
(iii)
(a)
(i)
(ii)
(iii)
(b)
(i)
(ii)
(iii)
(c)
(i)
(ii)
(iii)
(d)
Figure 4: Immunoﬂourescence staining of pluripotent markers in EiPS cells. Immunostaining of EiPS cells for (a) OCT4,( b )NANOG,( c )
SSEA1, and (d) SSEA4, counterstained with DAPI, scale bar 200μM.
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Figure 5: Diﬀerentiation potential of EiPS cells. (a) Embryoid body formation of EiPS cells grown in suspension medium in the absence of
LIF. (b) Single EB, scale bar 500μM. (c) Gene expression proﬁle of EiPS cells following diﬀerentiation of embryoid body. (d) Histology of
diﬀerentiated tissues found in the hind leg muscle of SCID mice following injection of EiPS cells included (i) endodermal diﬀerentiation,
(ii) mesodermal diﬀerentiation, (iii) ectodermal (neuroblastic) diﬀerentiation, scale bar 100μM.8 Stem Cells International
provide pluripotent cells that can be immunocompatible
to the recipient. There is one report on induction of plu-
ripotency in equine [29], using the Yamanaka cocktail
(OSKM) to generate iPS cells from fetal cells. In this study
we report the generation of equine iPS cells from adult cells
and without the use of the protooncogene c-MYC which
opens the door for autologous transplantation in cartilage
andtendoninjurymodels.SimilartotheﬁndingofNagyand
colleaguestheequineiPScellsgeneratedrequiredcontinuous
expression of the transgenes to maintain pluripotency. Apart
from one report in sheep [21], iPS cells generated in
other domestic species have shown similar traits [12, 18,
24, 25, 28], suggesting that maintenance of pluripotency
largely depends on the expression of the reprogramming
transgenes.
We established the equine iPS cell line which proliferated
in culture beyond 27 passages. The cells maintained ESC
characteristics and expressed pluripotent markers including
alkaline phosphatase activity and expression of pluripotency
markers OCT4 and NANOG. Furthermore, the cells stained
positively for SSEA1 similar to mouse pluripotent cells; as
wellasSSEA4whichisexpressedonhumanpluripotentcells,
similarﬁndingshavebeenreportedinequineES[11,12]and
iPS cells [29]. The EiPS cells expressed pluripotency genes
OCT4, SOX2, NANOG,a n dSTAT3 by RT-PCR. The EiPS
cells showed diﬀerentiation potential in vitro by EB forma-
tion and expressing genes indicative of the three embryonic
germ layers. Some of the discrepancies in the markers are
due to the diﬃculties in characterizing pluripotency in the
horse as there is a lack of reliable pluripotency markers [1]
and lack of suitable antibodies raised against equine cells
for immunocytochemical analyses [29]. Therefore, in vivo
diﬀerentiation by teratoma formation was used as further
evidence of pluripotential of the cells as has been routinely
conducted for iPS cells from most domestic species.
In summary, our ﬁndings indicate that adult equine
ﬁbroblast can be reprogrammed into pluripotent state via
the retroviral delivery of transcription factors, OCT4, SOX2,
and KLF4. The generated iPS cells are pluripotent as shown
by expression of pluripotent markers and have capability to
diﬀerentiate into cell types indicative of the three embryonic
germ layers both in vitro and in vivo.
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